Basel, Switzerland, December 29, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced that, as of January 1, 2017, Ursula Eberhardt will take the role of Head of Global Human Resources and join the Extended Management Committee which reports to the Chief Executive Officer. Ms. Eberhardt succeeds Heidi McDaid, who retires as of December 31, 2016. Ms. Eberhardt has served in various positions in Basilea's Corporate Department and Human Resources team since joining Basilea in 2006 and most recently was deputy Head of Global Human Resources.
Ronald Scott, Basilea's Chief Executive Officer, indicated: "Basilea greatly appreciates Ms. McDaid who built Basilea's human resources department and operations from our founding to a level of industry excellence. Basilea's human resources activities will continue to be in good hands under Ms. Eberhardt, who has been our deputy Head of Global Human Resources for the last seven years. We wish Ms. McDaid all the best in her retirement and much success to Ms. Eberhardt in her new position."
About Basilea
Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products that address increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
| Peer Nils Schröder, PhD Head of Corporate Communications & Investor Relations +41 61 606 1102 [email protected] [email protected] |
This press release can be downloaded from www.basilea.com.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/d56fddc3-2502-430d-adbc-9a2ff077d4bd


Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Shell M&A Chief Exits After BP Takeover Proposal Rejected
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 



